JVM Co

JVM Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of JVM Co (054950.KQ) as of Oct 29, 2026 is 10.43 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 10.77 % — a change of -3.19% (lower).

EBIT/Assets

10.43 %

YoY

-3.19%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of JVM Co is 2025 10.43 % . Operating Income to Assets Ratio (EBIT/Assets) of JVM Co was 2024 10.77 % . It decreases by -3.19% lower compared to the previous year.

The JVM Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
5.25 KRW
Jan 1, 2019
3.30 KRW
Jan 1, 2020
6.46 KRW
Jan 1, 2021
5.30 KRW
Jan 1, 2022
8.62 KRW
Jan 1, 2023
11.56 KRW
Jan 1, 2024
10.77 KRW
Jan 1, 2025
10.43 KRW
The JVM Co EBIT/Assets history
YEAREBIT/AssetsYoY
10.43 %-3.19%
10.77 %-6.83%
11.56 %+34.10%
8.62 %+62.81%
5.30 %-17.99%
6.46 %+95.77%
3.30 %-37.22%
5.25 %-23.00%
6.82 %+2.38%
6.66 %+128.82%
2.91 %-58.90%
7.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JVM Co Stock analysis

What does JVM Co do? JVM Co., Ltd. manufactures pharmacy automation systems under the brand JVM, targeting domestic and overseas markets. The company's primary products include automatic tablet dispensing and packaging systems (ATDPSs), automatic tablet classification and packing machines available in slide, box, and drum types, total safety solutions, automatic medication vision inspection systems (VIZENs), automatic package cutting and winding systems (WIZERs), and automatic medication sorting and control systems (AccuPharm). These products are sold to customers in the pharmaceutical and healthcare sectors seeking efficient automation solutions for medication handling and safety. The firm generates revenue through the sale of its branded automation systems, with a focus on domestic distribution and international markets. JVM's product portfolio addresses key operational needs in pharmacy settings, including dispensing, classification, inspection, and sorting of medications, ensuring compliance with safety standards while improving workflow efficiency. The company's offerings are designed to meet the demands of healthcare providers and pharmaceutical manufacturers requiring advanced automation technologies. JVM's business model centers on providing comprehensive automation solutions for pharmacy operations, leveraging its established brand JVM to differentiate its products in the market. By offering a wide range of specialized systems, the company caters to both domestic and international clients seeking reliable, high-quality automation equipment for medication management and safety protocols. JVM Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JVM Co stock

Operating Income to Assets Ratio (EBIT/Assets) of JVM Co is 10.43 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of JVM Co changed from 10.77 % to 10.43 %, representing a -3.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) JVM Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s JVM Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — JVM Co

All Key Metrics — JVM Co